The total net revenue for the year ended December 31, 2024 of approximately $11.7 million for prescription and non-prescription products, ...

"As a cancer patient, having options to manage the side effects of life saving drugs is very important. I believe the published results of crofelemer for the prophylaxis of CTD are very exciting and ...

Jaguar Health (JAGX) announced that the U.S. Food and Drug Administration has granted Napo a Type C Meeting in the second quarter of 2025 to ...

In ONTARGET patients, glomerular filtration rate (GFR) decline averaged 0.9 ml/min per year, which is within the physiologic range of GFR loss (0.6–1.1 ml/min per year) observed in healthy ...

The statistically significant responder analysis results for Mytesi ® (crofelemer) in the OnTarget study's prespecified subgroup of patients with breast cancer were the subject of a December 2024 ...

with additional POC IIT results expected throughout 2025 FDA meeting in the second quarter of 2025 on the statistically significant results of the Phase 3 OnTarget trial of crofelemer in the ...